Apalutamide for prostate cancer: Multicentre and multidisciplinary real‐world study of 227 patients
Julián Córdoba Sánchez(Hospital Clínic de Barcelona), Antoni Vilaseca(Hospital Clínic de Barcelona), Alejandra Bravo(Universidad Autónoma del Estado de Morelos), Josep María Gaya(Puigvert Foundation), Oscar Buisán(Bellvitge University Hospital), José Francisco Suárez(Hospital Universitario Nuestra Señora de Candelaria), Mireía Musquera(Surgical Specialties (Canada)), Meritxell Pérez Márquez(Consorci Sanitari de Terrassa), Pol Servián(Hospital Universitari Germans Trias i Pujol), Antonio Alcaraz(Hospital Clínic de Barcelona), Alejo Rodríguez‐Vida(Hospital Del Mar), David Marmolejo Castañeda(Vall d'Hebron Hospital Universitari), Jesús Muñoz Rodríguez(Deleted Institution), Natàlia Picola(Bellvitge University Hospital), Maria Jose Ribal Caparrós(Hospital Clínic de Barcelona)
Cited by 8
Related Papers
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
Efficacy of genetically modified Bt toxins against insects with different genetic mechanisms of resistance
|Nature Biotechnology|2011|150
Robot-assisted Kidney Transplantation: The European Experience
|European Urology|2017|143